You are here: Industry Insights > Shire

News List

Shire Receives FDA Fast Track Designation for Recombinant ADAMTS13 for Treatment of Hereditary Throm americanpharmaceuticalreview
March 23, 2017
Shire announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for recombinant ADAMTS13 (SHP655 - historically known as BAX930) for treatment of acute episodes...
Shire Receives European Approval for Label Extension of CINRYZE to Prevent and Treat Hereditary Angi americanpharmaceuticalreview
March 17, 2017
Shire announced that the European Commission (EC) has approved a label extension granting three new indications for CINRYZE® (C1 inhibitor [human])...
SMC welcomes Roche’s Gazyvaro but rejects Shire’s Onivyde pharmatimes
March 15, 2017
Patients with follicular lymphoma in Scotland have gained a new treatment option for the condition after the Scottish Medicines Consortium (SMC) published advice accepting Roche’s Gazyvaro for routine use by NHS Scotland.
CHMP recommends EU Conditional Marketing Authorisation for Natpar for patients with chronic hypopara cphi-online
March 01, 2017
If approved, Natpar would be the first licensed recombinant parathyroid hormone in Europe for the management of chronic hypoparathyroidism, the only endocrine-deficiency disorder with no hormone treatment.
Baxalta buy drives huge leap in Shire’s Q4 sales pharmatimes
February 20, 2017
Shire has booked sales of $3.62 billion for the fourth quarter, marking a leap of 123 percent driven by its acquisition of Baxalta last year.
Shire's fourth-quarter sales more than double, lifted by Baxalta firstwordpharma
February 17, 2017
Shire's fourth-quarter revenue more than doubled year-over-year to $3.8 billion, in line with analyst estimates, boosted by the purchase of Baxalta, the company reported Thursday. Net income in the three-month period jumped 63 percent to $457 million.
Shire Reports Full Year 2016 Results with Record Revenue americanpharmaceuticalreview
February 17, 2017
Shire has announced unaudited results for the year ended December 31, 2016.
Shire refiles ADHD drug pharmatimes
January 22, 2017
Shire has refiled its experimental attention deficit hyperactivity disorder drug SHP 465 in the US, having garnered new data further backing its safety and efficacy.
Shire sells mRNA therapy platform to RaNA Therapeutics firstwordpharma
January 05, 2017
Shire sold its mRNA therapy platform to RaNA Therapeutics in return for an undisclosed equity stake, as well as future milestones and royalties on products developed with the technology, RaNA announced Wednesday.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page